XML 116 R102.htm IDEA: XBRL DOCUMENT v3.8.0.1
EQUITY METHOD INVESTMENTS (Narrative) (Details)
¥ in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
May 31, 2017
May 17, 2017
USD ($)
Sep. 29, 2016
CNY (¥)
Sep. 29, 2016
USD ($)
Jul. 31, 2015
CNY (¥)
Dec. 31, 2017
CNY (¥)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
CNY (¥)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
CNY (¥)
Dec. 31, 2015
USD ($)
Dec. 28, 2012
CNY (¥)
Dec. 31, 2017
USD ($)
Jul. 20, 2017
Apr. 30, 2017
USD ($)
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Share of net profit (loss)           ¥ 1,454 $ 223 ¥ 616   ¥ (5,572)          
Cash distribution from an equity investee           6,227 957 9,357   ¥ 24,316          
Fair value of identified net asset on acquisition date         ¥ 19,658             ¥ 73,570      
Business Combination, Consideration Transferred     ¥ 41,670 $ 6,002       100,000 $ 14,403            
Equity Method Investments           732,167   210,088         $ 112,532    
Equity Method Investment, Ownership Description  In May 2017, the Group through its subsidiary Aohua Technology, acquired 31.64% equity interest of ProMed at a consideration of RMB105,119 (US$16,156) from the original shareholder.                            
Authorised capital           3,000                  
Percentage of interest held                             55.00%
Proceeds from Contributed Capital | $             3,000                
Other Long-term Debt           280,459             43,105    
Redeemable Noncontrolling Interest, Equity, Carrying Amount           396,281   ¥ 0         $ 60,907    
Tianjin Jiatai [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Capital Contributed           ¥ 2,700                  
Percentage of interest held           90.00%             90.00%    
Guofu Huimei [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Noncontrolling Interest, Ownership Percentage by Parent           20.41%             20.41%    
Mhm [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Capital Contributed           ¥ 300                  
Percentage of interest held           10.00%             10.00%    
Beijing Century Friendship [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Equity Method Investments           ¥ 100,614             $ 15,464    
Capital Contributed | $                             $ 388,500
Percentage of interest held           21.69%             21.69%    
Bpmc [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Percentage of interest held           25.00%             25.00%    
Suzhou Chorus Medical Technologies Co., Ltd [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Equity Method Investment, Ownership Percentage           36.00% [1]   36.00% [1]   36.00% 36.00%   36.00% [1]    
Business Combination, Consideration Transferred                   ¥ 4,320 $ 622        
Global Oncology One, Inc [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Equity Method Investment, Ownership Percentage           46.90% [1]   46.90% [1]   46.90% 46.90%   46.90% [1]    
Business Combination, Consideration Transferred                   ¥ 8,679 $ 1,250        
PeoMed [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Equity Method Investment, Ownership Percentage           35.20%             35.20%    
Business Combination, Consideration Transferred | $   $ 11,820                          
PeoMed [Member] | Guofu Huimei [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Equity Method Investment, Ownership Percentage                           31.64%  
PeoMed [Member] | CHMG [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Equity Method Investment, Ownership Percentage           3.56%             3.56%    
PTC [Member]                              
Schedule Of Results Related To Equity Accounted Investees [Line Items]                              
Share of net profit (loss)         34,206 ¥ 17,697 2,720 ¥ 127   ¥ 5,572   107,139      
Cash distribution from an equity investee         ¥ 30,063 ¥ 6,227 $ 957 ¥ 9,357       ¥ 201,176      
Equity Method Investment, Ownership Percentage           59.51% [2]   59.51% [2]       44.55% 59.51% [2]    
Noncontrolling Interest, Ownership Percentage by Parent         59.51%             1.00%      
[1] In 2015, the Group entered into two share transfer agreements with JWYK, which was controlled by one of the Group's directors. Pursuant to the agreements, JWYK would acquired 36% equity interest in Suzhou Chorus and 100% interest in China Medstar, an oversea subsidiary of the Company who holds 46.9% equity interest in Global Oncology from the Group, at a consideration of RMB4,320 (US$622) and RMB8,679 (US$1,250) respectively. On April 25, 2016 and November 10, 2016, the Group received full payments from JWYK. As of December 31, 2017, the changes in registration of shareholders have not been completed and the consideration received was recorded in accrued expenses and other liabilities on the consolidated balance sheets (note 19).
[2] On December 28, 2012, the Group acquired 44.55% limited partner interests of PTC, a limited partnership in Texas, U.S.A., and 45% legal interest of PTC GP Management LLC, a limited liability company registered in Texas, U.S.A and the sole general partner of PTC with 1% interest of PTC, with a consideration of RMB201,176 in cash. On July 31, 2015, the Group acquired additional 14.34% limited partner interests of PTC and additional 17.07% legal interest of PTC GP Management LLC, with a consideration of RMB30,063in cash. After the additional investments, the Group owned 59.51% interests of PTC which ultimately holds 45.41% legal ownership interests of the University of Texas MD Anderson Cancer Center Proton Therapy Center (“MDA Proton”), a proton treatment center in Texas, U.S.A. In accordance with PTC GP Management LLC’s regulation, the Group is only entitled to designate two out of the five managers and simply majority (more than 50%) amongst the managers is required to pass any resolution. Furthermore the regulation can only amended at the request by managers or super majority (more than 2/3) of member interest. Thus the Group is not able to control PTC GP Management LLC. According to the partnership agreements, the Group has significant influence over PTC which can demonstrate control over MDA Proton by acting as the sole general partner. The Group accounts for its investment in PTC, and ultimately MDA Proton, under the equity method of accounting. The Group’s share of the net profit or loss of PTC, after accounting for the effect of the difference between the cost basis of the equity method investment and the underlying assets of the investee, was a loss of RMB5,572 a loss of RMB127 and a loss of RMB 17,697 (US$ 2,720) for the years ended December 31,2015 2016 and 2017 respectively. Total cash distribution received by the Group from PTC was RMB24,316,RMB9,359 and RMB 6,227 (US$ 957) for the years ended December 31, 2016and 2017, respectively. The differences between the carrying value of the investment in PTC and the underlying equity in the net assets of PTC was RMB107,139 and RMB34,206 on December 28, 2012 and July 31, 2015, respectively, which were mainly arisen from the identified intangibles in the purchase price allocation and are amortized in the remaining useful life.. The amount of the Group’s underlying equity in the net assets of PTC was RMB73,570 and RMB19,658 on December 28, 2012 and July 31, 2015, respectively.